Pharmacology & Pharmacy

Volume 4, Issue 1 (January 2013)

ISSN Print: 2157-9423   ISSN Online: 2157-9431

Google-based Impact Factor: 0.67  Citations  

Pharmacokinetic Prediction of Levofloxacin Accumulation in Tissue and Its Association to Tendinopathy

HTML  XML Download Download as PDF (Size: 680KB)  PP. 121-131  
DOI: 10.4236/pp.2013.41018    4,940 Downloads   8,962 Views  Citations

ABSTRACT

Objectives: We investigated pharmacokinetic tissue distributions of Levofloxacin to explain adverse tendon incidents. Methods: The pharmacokinetic profiles of single and multiple dosing of 500 mg Levofloxacin following oral and IV infusion administration were simulated. Monte Carlo simulation was used to simulate the drug concentration profiles in plasma and tissue after seven dosing regimens while varying the drug’s elimination and distribution rates to analyze the effects of changing those rates on Levofloxacin accumulation in tissue. Results: Simulated data following oral and IV administration reflect well the reported data (mean simulated plasma Cmax = 6.59 μg/mL and 5.19 μg/mL for IV and oral versus 6.4 μg/mL and 5.2 μg/mL for observed clinical IV and oral route, respectively). Simulations of seven repetitive doses are also in agreement with reported values. Low elimination rates affect the drug concentration in plasma and tissue significantly with the concentration in plasma rising to 35 μg/mL at day 7. Normal elimination rates together with escalation of distribution rates from plasma to tissue increase tissue concentration after 7 doses to 9.5 μg/mL, a value is more than twice that of normal. Conclusions: Simulation can be used to evaluate drug concentration in different tissues. The unexpectedly high concentrations in some cases may explain the reason for tendinopathy in clinical settings.

Share and Cite:

Pham, L. , Christensen, J. and Rodriguez-Proteau, R. (2013) Pharmacokinetic Prediction of Levofloxacin Accumulation in Tissue and Its Association to Tendinopathy. Pharmacology & Pharmacy, 4, 121-131. doi: 10.4236/pp.2013.41018.

Cited by

[1] Ratlarda Salbutamol'ün Levofloksasin'in Akciğer Dokusuna Geçişine Etkisi
2022
[2] Ratlarda N-Asetilsistein'in Levofloksasin'in Akciğer Dokusuna Geçişine Etkisi
2022
[3] ROLE OF LEVOFLOXACIN FOR TREATMENT OF CHRONIC SUPPURATIVE OTITIS MEDIA: SAMPLE OF IRAQI PATIENTS
2017
[4] Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body …
2014
[5] Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI [Greater-Than Or Equal To] 40 kg/m^ sup 2^) Should Be Guided by Creatinine Clearance …
2014
[6] Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI≥ 40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring
Clinical pharmacokinetics, 2014
[7] Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI [Greater-Than Or Equal To] 40 kg/m^ sup 2^) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring
Clinical Pharmacokinetics, 2014

Journals Menu
Follow SCIRP
Contact us
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.